Ripasudil

Drug Profile

Ripasudil

Alternative Names: Glanatec; K-115; K-115-R; Ripasudil hydrocholoride hydrate

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer Kowa Pharmaceutical
  • Class Azepines; Eye disorder therapies; Fluorine compounds; Isoquinolines; Small molecules; Sulfonamides
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase II Diabetic retinopathy

Most Recent Events

  • 01 Apr 2017 Kowa initiates enrolment in a clinical trial for Glaucoma in Japan (JapicCTI-173562)
  • 28 Feb 2017 Phase-II development for Diabetic retinopathy is ongoing in Japan (Ophthalmic)
  • 02 Dec 2014 Launched for Glaucoma (Combination therapy, Monotherapy) in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top